Print Page      Close Window     


SEC Filings

OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document



NOLASIBAN (OBE001): Oral oxytocin receptor antagonist to improve IVF outcomes NOLASIBAN AT-A-GLANCE Oxytocin Receptor Antagonist Licensed from Merck Serono IP Protection to 2035-2036 (COM 2027 with PTE) NOLASIBAN INDICATIONS In Vitro Fertilization (IVF) Market size: 2.1-2.4 million ART cycles/year globally in 2013* (230K in US in 2015, 800K in Europe in 2014 and 420K in Japan in 2015) ART cycle cost: $8-15K in the US, EUR 2-10K in the EU and $3-6k in Japan Estimated global sales of fertility drugs 2 bn USD** LANDSCAPE Atosiban (Tractocile®) approved ex-US for Preterm labor I.V. peptide No label for IVF use NOLASIBAN: Well-characterized profile, Phase 2 clinical trial completed, EU Phase 3 primary endpoint completed 650 subjects exposed Orally active—Well tolerated tmax at 2h; t1/2= 12h; High bioavailability Single oral 900mg optimal dose * Source: ICMART 2013 estimate; **IMS Health Incorporated estimate as of 2015.